Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Combination of antigens from multiple viral species
Reexamination Certificate
2007-01-30
2007-01-30
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Combination of antigens from multiple viral species
C424S184100, C424S204100, C424S206100, C424S211100, C424S278100, C530S300000, C530S350000
Reexamination Certificate
active
09868177
ABSTRACT:
Immunogenic compositions for administration to adults, particularly to the elderly, to protect them against disease caused by infection by respiratory syncytial virus and by influenza virus comprise an immunoeffective amount of a mixture of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of RSV and an immunoeffective amount of a non-virulent influenza virus preparation. The components of the composition, when formulated as a vaccine for in vivo administration, do not impair the immunogenicity of each other. The immunogenic composition may also contain an adjuvant.
REFERENCES:
patent: 5494673 (1996-02-01), Andrianov et al.
patent: 5612037 (1997-03-01), Huebner et al.
patent: 5762939 (1998-06-01), Smith et al.
patent: 5824536 (1998-10-01), Webster et al.
patent: 5911998 (1999-06-01), Potash et al.
patent: 6020182 (2000-02-01), Cates et al.
patent: 6022726 (2000-02-01), Palese et al.
patent: 6309649 (2001-10-01), Cates et al.
patent: 2002/0136739 (2002-09-01), Cates et al.
patent: WO 95/02628 (1995-01-01), None
patent: WO 95/34308 (1995-12-01), None
patent: WO 95/34323 (1995-12-01), None
patent: WO 96/33738 (1996-10-01), None
patent: WO 98/02457 (1998-01-01), None
Groothuis et al., “Safety and Immunogenicity of a Purified F Protein Respiratory Syncytial Virus (PFP-2) Vaccine in Seropositive Children with Bronchopulmanary Dysplasia,” Journal of Infectious Diseases, vol. 177(2), pp. 467-469 (1998).
Falsey et al., ., “Safety and Immunogenicity of a Purified F Protein Respiratory Syncytial Virus (PFP-2) Vaccine in Ambulatory Adults over Age 60,” Vaccine, vol. 14(13), pp. 1214-1218 (1996).
Crowe, Vaccine, vol. 13, pp. 415-421 (1995).
Hall et al., “Immunity to and Frequency of Reinfection with Respiratory Syncytial Virus,” J. Infect. Dis., vol. 163, pp. 693-698 (1991).
Tang et al., Journal of Virology, vol. 77 No. 20, pp. 10819-10828 (Oct. 2003).
Prince et al., Journal of Virology, vol. 74 No. 22, pp. 10287-10292 (Nov. 2000).
Dudas et al., Clinical Microbiology Reviews, vol. 11 No. 3, pp. 430-439 (Jul. 1998).
Mlinaric-Galinovic G, Falsey AR, Walsh EE, 1996. Respiratory syncytial virus infection in the elderly. Eur J Clin Microbiol Infect Dis 1996.
Collins, P., McIntosh, K., and Chanock, R.M. in “Fields Virology” ed. by Fields, B.N., Knipe, D.M., and Howley, P.M., Lippincott-Raven Press, New York, (1996) pp. 1313-1351.
Walsh, E.E., Hall, C.B., Briselli, M., Brandiss, M.W. and Schlesinger, J.J. (1987) J. Infect. Dis. 155, 1198-1204.
Walsh, E.E., Hruska, J. (1983) J. Virol. 47, 171-177.
Levine, S., Kleiber-France, R., and Paradiso, P.R. (1987) J. Gen. Virol. 69, 2521-2524.
Anderson, L.J. Hierholzer, J.C., Tsou, C., Hendry, R.M., Fernie, B.F., Stone, Y. and McIntosh, K. (1985), J. Infect. Dis. 151, 626-633.
Johnson, P.R., Olmsted, R.A., Prince, G.A., Murphy, B.R., Alling, D.W., Walsh, E.E. and Collins, P.L. (1987) J. Virol. 61 (10), 3163-3166.
Cherrie, A.H., Anderson, K., Wertz, G.W., and Openshaw, P.J.M. (1992) J. Virology 66, 2102-2110.
Kim, H.W., Canchola, J.G., Brandt, C.D., Pyles, G., Chanock, R.M. Jensen, K., and Parrott, R.H. (1969) Amer. J. Epidemiology 89, 422-434.
Friedewald, W.T., Forsyth, B.R., Smith, C.B., Gharpure, M.S., and Chanock, R.M. (1968) JAMA 204, 142-146.
Walsh, E.E., Brandriss, M.W., Schlesinger, J.J. (1985) J. Gen. Virol. 66, 409-415.
Walsh, E.E., Schlesinger, J.J. and Brandriss, M.W. (1984) J. Gen. Virol. 65, 761-766.
Routledge, E.G., Wilcocks, M.M., Samson, A.C.R., Morgan, L., Scott, R., Anderson, J.J., and Toms, G.L. (1988) J. Gen. Virology 69, 293-303.
Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, I.W., Minamitani, M. and Meiklejohn, G. (1969) Am J.Epidemiol. 89 (4), 435-448.
Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J. H. and Lennette, E.H. (1969) Am. J. Epidemiol. 89 (4), 449-463.
Kapikian, A.Z., Mitchell, R.H., Chanock, R.M., Shvedoff, R.A. and Stewart, C.E. (1969) Am. J.Epidemiol. 89 (4),405-421.
Kim, H.W., Arrobio, J.O., Pyles, G., Brandt, C.D. Camargo, E., Chanock, R.M. and Parrott, R.H. (1971) Pediatrics 48, 745-755.
Wright, P.F., Belshe, R.B., Kim, H.W., Van Voris, L.P. and Chanock, r.M. (1982) Infect. Immun. 37 (1), 397-400.
Wright, P.F., Chinozaki, T. and Fleet, W. (1976) J. Pediatr. 88, 931-936.
Belshe, R.B., Van Voris, P. and Mufson, M.A. (1982) J. Infect. Dis. 145, 311-319.
Murphy, B.R, Prince, G.A., Walsh, E.E., Kim, H.W., Parrott, R.H., Hemming V.G., Rodriguez, W.J., and Chanock, R.M.. J. Clin. Microbiol. (1986), 24(2), 197-202.
Connors, M., Collins, P.L., Firestone, C.Y., Sotnikov, A.V., Waitze, A., Davis, A.R., Hung, P.P., Chanock, R.M., Murphy, b. (1992) Vaccine, 10, 475-484.
Prince, G.A., Jenson, A.B., Hemming, V.G., Murphy, E.R., Walsh, E.E., Horswood, R.L. and Chanock, R.L. (1986b) J. Virol. 57 (3), 721-728.
Piedra, P.A., Camussi, F. and Ogra, P.L. (1989) J. Gen. Virol. 70, 325-333.
Payne G.L., et al. Vaccine vol. 16, pp. 92-98 1998.
Fattom Ali et al. Vaccine 17 (1999) pp. 126-133.
Ambrosch F. et al., Combined vaccination against yellow fever . . . Vaccine 1994 vol. 12; pp. 625-628.
Frey Sharon et al., The Journal of Infectious Diseases 1999; 180:2018-2022.
Insel. A. Richard., Potential alterations in Immnogenicity by Combining or Simultaneously Adminstering Vaccine Components. pp. 35-47.
Plotkin A.S. & Orenstein A.W. Vaccines Third Edition. pp. 508-530.
Glezen, W.P., Paredes, A. Allison, J.E., Taber, L.H. and Frank, A.L. (1981), J. Pediatr. 98, 708-715.
Chanock, R.M., Parrot, R.H., Connors, M. Collins, P.L. and Murphy, B.R. (1992) Pediatrics 90, 137-142.
Martin, A.J. Gardiner, P.S. and McQuillin, J. (1978). Lancel II, 1035-1038.
Robbins, A., and Freeman, P. (1988) Sci. Am. 259, 126-133.
Glezen, W.P., Taber, L.H., Frank, A.L. and Kasel, J.A. (1986) Am. J. Dis. Child. 140, 543-546.
Katz, S.L. New vaccine development establishing priorities. vol. 1. Washington: National Academic Press. (1985) pp. 397-409.
Wertz, G.W., Sultender, W.M. (1992) Biotech. 20, 151-176.
McIntosh, K. and Chanock, R.M. (1990) in Fields Virology (Fields, B.M., and Knipe, D.M. eds.) pp. 1045-1075, Raven Press, Ltd., New York.
Murray AR, Dowell SF, 1997. Respiratory syncytial virus: not just for kids. Hosp. Pract. (Off Ed) Jul. 15, 1997; 32(7): 87-8, 91-4.
Burt David
Cates George A.
Klein Michel H.
Sambhara Suryaprakash
Campell Bruce R.
Lucas Zachariah
Sanofi Pasteur Limited
Sim & McBurney
Stewart Michael I.
LandOfFree
Multivalent immunogenic composition containing RSV subunit... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multivalent immunogenic composition containing RSV subunit..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multivalent immunogenic composition containing RSV subunit... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3749831